Back to search

Article

The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland

2023-06-12

Abstract excerpt

<h4>Objectives</h4> The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence who approved monotherapy alone in England and Wales. We aimed to provide real-world performance data for...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a20b6c86-c858-549b-9228-fb006f1724d7
DOI
10.1101/2023.06.08.23290541
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in ScotlandDOI 10.1101/2023.06.08.23290541
Real-Life Benefit and Costs of First Line Pembroli-zumab for Advanced NSCLC—A Propensity-Score Matched Case-Control StudySemantic proximity
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.Semantic proximity
Comparative effectiveness of first line pembrolizumab vs. chemotherapy in aNSCLC: A Norwegian Population-Based Cohort StudySemantic proximity
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England.Semantic proximity
Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)Semantic proximity
Albumin Paclitaxel Plus Platinum With or Without Pembrolizumab for Metastatic Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Retrospective Multicenter StudySemantic proximity
Effectiveness and Durable Outcomes with Second-Line Immunotherapy in Advanced NSCLC in Real World Practice in IndiaSemantic proximity
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.Semantic proximity
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic CenterSemantic proximity
Repurposing WHO Essential Antifungals for Cancer Treatment - Protocol for a Systematic Review and Cancer Dependency Map AnalysisSemantic proximity
Selection and Validation of Chemotherapy Beneficiaries among Elderly Nasopharyngeal Carcinoma (NPC) Patients Treated with Intensity-Modulated Radiation Therapy (IMRT): A Large Real-World StudySemantic proximity
A potential alternative systemic treatment option for epithelioid sarcomaSemantic proximity
Select a neighboring publication to make it the new centre.